Cannabis Science and World AIDS Institute Announce Appointment of Dr. Robert Melamede to Scientific Advisory Board
Cannabis Science Inc (NASD OTC: CBIS) and the World AIDS Institute announced today the appointment of Robert Melamede, PhD, Professor of Biology at the University of Colorado, Colorado Springs and CEO of Cannabis Science, to its Scientific Advisory Board. The World AIDS Institute recently announced the establishment of the Timothy Ray Brown Foundation, which aims to help advance the search for an HIV cure through the facilitation of collaborate efforts among industry, government, private and non-profit entities.
“We are extremely pleased to have Dr. Melamede join our Scientific Advisory Board,” said Dave Purdy, Founder and CEO of the World AIDS Institute. “We feel the World AIDS Institute will benefit considerably from Dr. Melamede’s expertise on a number of HIV related issues. His insight is invaluable, as is the commitment and passion he brings to finding novel treatments in the fight against HIV/AIDS. We look forward to a long standing relationship with Dr. Melamede.”
Dr. Melamede, who presented at the World AIDS Institute's Treatment Horizons Satellite Symposium during the XIX International AIDS Conference in Washington, DC this past July, is deeply dedicated to those impacted by HIV and has expressed a strong desire to assist in the realization of the World AIDS Institute’s mission. “The World AIDS Institute’s efforts towards the discovery of a cure for HIV, as well as their work to document and preserve the history of the AIDS crisis, makes them an important asset not only to those in the field of HIV but to the world and will remain so for generations to come. I am honored to be asked to participate in their endeavor,” stated Dr. Melamede.
Cannabis Science’s newly established CS-TATI-1 research program is focused on the development of CB1/CB2 agonists and antagonists for the treatment of AIDS-related Kaposi Sarcoma (KS). AIDS-related KS is the third leading cause of death of people living with HIV in Sub-Saharan Africa. Incidence of KS in the U.S. declined significantly after the initiation of HIV antiretroviral therapy in 1996; however, over the past several years a growing reemergence of KS in virally suppressed patients on HAART has indicated a need for new treatments for KS.